Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,037 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pilot postal birth cohort HCV Screening in UK primary care.
Simmons R, Powell A, Ijaz S, Mandal S, Shute J, Mohammadi Y, Lattimore M, McOwat K, Moore H, O'Rourke A, Desai M, MacLeod J, Asgharzadeh A, Ward Z, Vickerman P, Harris R, Foster G, Roberts K, Hickman M. Simmons R, et al. Among authors: foster g. Br J Gen Pract. 2024 Jul 5:BJGP.2024.0219. doi: 10.3399/BJGP.2024.0219. Online ahead of print. Br J Gen Pract. 2024. PMID: 38969354
Evaluating the effect of direct-acting antiviral agent treatment scale-up on Hepatitis C virus prevalence among people who inject drugs in UK.
Samartsidis P, Harris RJ, Dillon J, Desai M, Foster GR, Gunson R, Ijaz S, Mandal S, McAuley A, Palmateer N, Presanis AM, Simmons R, Smith S, Thorne B, Yeung A, Zaouche M, Hutchinson S, Hickman M, Angelis D. Samartsidis P, et al. Int J Drug Policy. 2024 Jun 27:104429. doi: 10.1016/j.drugpo.2024.104429. Online ahead of print. Int J Drug Policy. 2024. PMID: 38942687 Free article.
Impact and cost-effectiveness of scaling up HCV testing and treatment strategies for achieving HCV elimination among people who inject drugs in England: a mathematical modelling study.
Ward Z, Simmons R, Fraser H, Trickey A, Kesten J, Gibson A, Reid L, Cox S, Gordon F, Mc Pherson S, Ryder S, Vilar J, Miners A, Williams J, Emmanouil B, Desai M, Coughlan L, Harris R, Foster GR, Hickman M, Mandal S, Vickerman P. Ward Z, et al. Among authors: foster gr. Lancet Reg Health Eur. 2024 Dec 12;49:101176. doi: 10.1016/j.lanepe.2024.101176. eCollection 2025 Feb. Lancet Reg Health Eur. 2024. PMID: 39759576 Free PMC article.
Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions.
Marshall AD, Willing AR, Kairouz A, Cunningham EB, Wheeler A, O'Brien N, Perera V, Ward JW, Hiebert L, Degenhardt L, Hajarizadeh B, Colledge S, Hickman M, Jawad D, Lazarus JV, Matthews GV, Scheibe A, Vickerman P, Dore GJ, Grebely J; Global HCV and HIV Treatment Restrictions Group. Marshall AD, et al. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):366-382. doi: 10.1016/S2468-1253(23)00335-7. Epub 2024 Feb 15. Lancet Gastroenterol Hepatol. 2024. PMID: 38367631 Review.
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.
Lawitz E, Gane E, Feld JJ, Buti M, Foster GR, Rabinovitz M, Burnevich E, Katchman H, Tomasiewicz K, Lahser F, Jackson B, Shaughnessy M, Klopfer S, Yeh WW, Robertson MN, Hanna GJ, Barr E, Platt HL; C-BREEZE-2 Study Investigators. Lawitz E, et al. J Viral Hepat. 2019 Sep;26(9):1127-1138. doi: 10.1111/jvh.13132. Epub 2019 Jul 11. J Viral Hepat. 2019. PMID: 31108015 Clinical Trial.
2,037 results